Actively Recruiting
Migraine and High Flow Oxygenotherapy at the Emergency Department (MiOx)
Led by Centre Hospitalier Universitaire de Nice · Updated on 2024-11-18
70
Participants Needed
1
Research Sites
78 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Migraine is a common pathology, affecting around 12% of the general population, up to 25% in some cohorts, as well as a significant part of the reasons for emergency room visits. Unlike cluster headaches, the use of high-flow oxygen therapy has not yet been validated in patients with migraine. However, several aspects of its pathophysiology, still studied to this day, suggest that the use of normobaric oxygen could have beneficial effects on migraine attacks: tissue hypoxia, cerebrovascular dysfunction with vasodilation, inflammation, etc. In addition, high-flow oxygen therapy has no significant side effects and almost no contraindication (mainly COPD and other chronic respiratory failure) Its use in the event of a migraine attack would thus allow less recourse to conventional analgesics (with significant side effects for some), a shorter stay in the emergency room, and therefore a benefit in terms of cost and relief for the patient. In this context, the sponsor wish to carry out a multicenter prospective interventional, single-blind randomized placebo-controlled in parallel groups study.
CONDITIONS
Official Title
Migraine and High Flow Oxygenotherapy at the Emergency Department (MiOx)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years old or more
- Affiliated to a French public health insurance
- Emergency department admission for headache consistent with migraine according to ICHD3 criteria
- Provided written informed consent
You will not qualify if you...
- COPD or other chronic respiratory failure conditions
- Pregnant or breastfeeding women or women of childbearing potential not using contraception (pregnancy test required for women of childbearing age)
- Under legal protection
- Received triptan treatment in the past 2 weeks
- Consumed NSAIDs in the hour before doctor's examination
- Migraine headache lasting more than 72 hours
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Nice
Nice, France, 06200
Actively Recruiting
Research Team
J
Julie CONTENTI
CONTACT
C
Céline OCCELLI
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here